Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01030640 · ClinicalTrials.gov registry record · Phase 1
Study To Assess Changes In The Number Of Nerves In The Skin At The Site Where Where Tanezumab Is Injected
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT01030640: Completed Phase 1 study, sponsored by Pfizer.
NCT01030640 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01030640, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
Subcutaneous administration of tanezumab can result in changes in the number of nerves around the injection site in the thigh.
Interventions
- OTHER placebo
- BIOLOGICAL tanezumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2009-12 |
| Est. Completion | 2010-09 |
| Phase | Phase 1 |
What the finished NCT01030640 record still lists
NCT01030640 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01030640 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01030640 about?
NCT01030640 is a clinical study titled "Study To Assess Changes In The Number Of Nerves In The Skin At The Site Where Where Tanezumab Is Injected". Subcutaneous administration of tanezumab can result in changes in the number of nerves around the injection site in the thigh.
What is the current status of trial NCT01030640?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2009-12. Estimated completion is 2010-09.
What interventions are being tested in trial NCT01030640?
The interventions under investigation include: placebo (OTHER), tanezumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01030640?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01030640's enrollment target sits among peer trials
28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia